86 related articles for article (PubMed ID: 12599782)
1. [Detection and clinical significance of CYFRA21-1 in serum of laryngeal carcinoma patients].
Luo R; Li G; Zhu C
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Jun; 16(6):289-91. PubMed ID: 12599782
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of the novel tumor marker CYFRA21-1 in patients with esophageal cancer].
Wang T; Zhang W; Liu Y
Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1390-1. PubMed ID: 11930636
[TBL] [Abstract][Full Text] [Related]
3. [Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer].
Mao YS; Zhang DC; Zhao XH; Wang LJ; Qi J; Li XX
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):457-60. PubMed ID: 14575569
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of combined detection of CYFRA21-1 and TSGF in nasopharyngeal carcinoma].
Huang L; Huang W; Chen Y
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Mar; 19(5):201-2. PubMed ID: 15934283
[TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
7. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
Tan Y; Zhang P; Zheng C
Zhonghua Zhong Liu Za Zhi; 1999 Jul; 21(4):287-9. PubMed ID: 11776818
[TBL] [Abstract][Full Text] [Related]
8. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
9. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
10. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
[TBL] [Abstract][Full Text] [Related]
12. Serum CYFRA21-1 as a prognostic marker for patients with undifferentiated nasopharyngeal carcinoma.
Zhu WQ; Yu JM; Sun XD; Xie P; Kong L
Biomarkers; 2010 Nov; 15(7):602-7. PubMed ID: 20726807
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S
Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666
[TBL] [Abstract][Full Text] [Related]
14. Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer.
Shimada H; Nabeya Y; Okazumi S; Matsubara H; Kadomatsu K; Muramatsu T; Ikematsu S; Sakuma S; Ochiai T
Oncol Rep; 2003; 10(2):411-4. PubMed ID: 12579281
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
[TBL] [Abstract][Full Text] [Related]
16. CYFRA21-1 as a serum tumor marker for follow-up patients with squamous cell lung carcinoma and oropharynx squamous cell carcinoma.
Liu L; Liu B; Zhu LL; Li Y
Biomark Med; 2013 Aug; 7(4):591-9. PubMed ID: 23905896
[TBL] [Abstract][Full Text] [Related]
17. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma.
Al-Shagahin H; Alkotyfan K; Müller HH; Sesterhenn AM; Werner JA
Anticancer Res; 2009 Aug; 29(8):3421-5. PubMed ID: 19661367
[TBL] [Abstract][Full Text] [Related]
18. [Studies of serum markers in patients with interstitial pneumonia/pulmonary fibrosis complicated with collagen diseases: clinical evaluation of CYFRA21-1].
Suzuki A; Masuda T; Koito N; Suzuki T; Mita S; Matsuoka Y; Irimajiri S
Ryumachi; 1996 Dec; 36(6):837-43. PubMed ID: 9122823
[TBL] [Abstract][Full Text] [Related]
19. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.
Yi Y; Li B; Wang Z; Sun H; Gong H; Zhang Z
Biomarkers; 2009 Nov; 14(7):480-5. PubMed ID: 19863186
[TBL] [Abstract][Full Text] [Related]
20. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
